registrieren | anmelden | FAQ      [?] 
Recent | Unread | Search | Authors | Tags | Export

worx11s library [902 articles]

Neue Artikel in worx11s Bibliothek.
  • Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Int Clin Psychopharmacol, Vol. 22, No. 2. (March 2007), pp. 107-115.
    by B Fantino, N Moore, H Verdoux, JP Auray
    posted to as depression by worx11 on 2007-10-18 17:22:13 as ** along with 1 group XROWXR
  • SSRIs versus other antidepressants for depressive disorder.
    Cochrane Database Syst Rev, No. 2. (2000)
    by JR Geddes, N Freemantle, J Mason, MP Eccles, J Boynton
    posted to as depression by worx11 on 2007-10-18 13:30:13 as ** along with 1 group XROWXR
  • WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
    Cochrane Database Syst Rev, No. 3. (2007)
    by C Barbui, M Hotopf, N Freemantle, J Boynton, R Churchill, MP Eccles, JR Geddes, R Hardy, G Lewis, JM Mason
    posted to as depression by worx11 on 2007-10-18 13:29:50 as ** along with 1 group XROWXR
  • WITHDRAWN: Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression.
    Cochrane Database Syst Rev, No. 3. (2007)
    by JR Geddes, N Freemantle, J Mason, MP Eccles, J Boynton
    posted to as depression by worx11 on 2007-10-18 13:29:29 as ** along with 1 group XROWXR
  • [Review of double-blind studies comparing SSRI and SNRI]
    Seishin Shinkeigaku Zasshi, Vol. 106, No. 10. (2004), pp. 1203-1217.
    by E Suzuki, S Maruta
    posted to as depression by worx11 on 2007-10-18 13:29:01 as ** along with 1 group XROWXR
  • An overview of SSRI and SNRI therapies for depression.
    Manag Care, Vol. 13, No. 6 Suppl Depression. (June 2004), pp. 25-33.
    by JB Weilburg
    posted to as depression by worx11 on 2007-10-18 13:28:33 as ** along with 1 group XROWXR
  • Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
    J Clin Psychiatry, Vol. 67, No. 12. (December 2006), pp. 1836-1855.
    by HG Ruhé, J Huyser, JA Swinkels, AH Schene
  • Management of diabetes in older adults.
    Am J Med Sci, Vol. 333, No. 1. (January 2007), pp. 35-47.
    by AA Rizvi
    posted to diabetes me senior_care_research by worx11 on 2007-10-10 14:50:46 as ** along with 1 group XROWXR
  • Improving quality of care for urban older people with diabetes mellitus and cardiovascular disease.
    J Am Geriatr Soc, Vol. 55, No. 10. (October 2007), pp. 1656-1662.
    posted to diabetes me senior_care_research by worx11 on 2007-10-10 14:50:19 as ** along with 1 group XROWXR
  • Management of diabetes in the hospital.
    Rev Cardiovasc Med, Vol. 7 Suppl 2 (2006)
    by V Fonseca
    posted to diabetes hospital me by worx11 on 2007-10-10 14:49:15 as **
  • Better glycemic control in the hospital: beneficial and feasible.
    Cleve Clin J Med, Vol. 74, No. 2. (February 2007)
    by S Clement
    posted to diabetes hospital me by worx11 on 2007-10-10 14:48:56 as ** along with 1 group XROWXR
  • Hospital protocols for targeted glycemic control: Development, implementation, and models for cost justification.
    Am J Health Syst Pharm, Vol. 64, No. 10 Suppl 6. (15 May 2007)
    by MF Magee
    posted to diabetes hospital me by worx11 on 2007-10-10 14:48:25 as ** along with 2 people and 1 group jyuh shamsha XROWXR
  • Hyperglycemia management in the hospital setting.
    Am J Health Syst Pharm, Vol. 64, No. 10 Suppl 6. (15 May 2007)
    by E Hassan
    posted to diabetes hospital me by worx11 on 2007-10-10 14:48:01 as ** along with 2 people and 1 group jyuh shamsha XROWXR
  • Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy.
    Pharmacotherapy, Vol. 26, No. 10. (October 2006), pp. 1421-1432.
    by LK Golightly, MA Jones, DH Hamamura, NM Stolpman, MT McDermott
  • An institutional process to improve inpatient glycemic control.
    Qual Manag Health Care, Vol. 16, No. 3. (p 2007), pp. 239-249.
    by LR Reynolds, AM Cook, DA Lewis, MC Colliver, SS Legg, NG Barnes, J Conigliaro, RP Lofgren
    posted to me diabetes hospital by worx11 on 2007-10-10 14:44:15 as ** along with 1 group XROWXR
  • Diabetes care in hospitalized noncritically ill patients: More evidence for clinical inertia and negative therapeutic momentum.
    J Hosp Med, Vol. 2, No. 4. (July 2007), pp. 203-211.
    by CB Cook, JC Castro, RE Schmidt, SM Gauthier, MD Whitaker, LR Roust, R Argueta, BP Hull, RS Zimmerman
    posted to diabetes hospital me by worx11 on 2007-10-10 14:43:44 as ** along with 1 group XROWXR
  • Treatment of hypoglycemia in hospitalized adults: a descriptive study.
    Diabetes Educ, Vol. 33, No. 4. (g 2007), pp. 709-715.
    by M Anthony
    posted to diabetes hospital me by worx11 on 2007-10-10 14:43:17 as ** along with 1 group XROWXR
  • Severe hypoglycemia in critically ill patients: Risk factors and outcomes*
    Crit Care Med (21 August 2007)
    by James S Krinsley, Aarti Grover
    posted to diabetes hospital me by worx11 on 2007-10-10 14:42:36 as ** along with 1 person and 1 group pstrasma XROWXR
  • RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes (RABBIT 2 Trial).
    Diabetes Care (18 May 2007)
    by Guillermo E E Umpierrez, Dawn Smiley, Ariel Zisman, Luz M M Prieto, Andres Palacio, Miguel Ceron, Alvaro Puig, Roberto Mejia
  • Chronically Critically Ill Patients: Health-Related Quality of Life and Resource Use After a Disease Management Intervention
    Am J Crit Care, Vol. 16, No. 5. (1 September 2007), pp. 447-457.
    by Sara L Douglas, Barbara J Daly, Carol G Kelley, Elizabeth O'Toole, Hugo Montenegro
  • Diabetes team consultation: Impact on length of stay of diabetic patients admitted to a short-stay unit.
    Diabetes Res Clin Pract, Vol. 78, No. 2. (November 2007), pp. 211-216.
    posted to diabetes hospital me by worx11 on 2007-10-10 14:39:55 as ** along with 1 group XROWXR
  • Raloxifene examined for breast cancer prevention.
    Am J Health Syst Pharm, Vol. 64, No. 17. (1 September 2007)
    by D Young
    posted to ac chemoprevention serm by worx11 on 2007-10-04 20:25:00 as ** along with 1 group XROWXR
  • Safety and efficacy of antiestrogens for prevention of breast cancer.
    Am J Health Syst Pharm, Vol. 57, No. 14. (15 July 2000)
    by P Reddy, MS Chow
    posted to ac chemoprevention serm by worx11 on 2007-10-04 20:23:53 as ** along with 1 group XROWXR
  • Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.
    Am J Ther, Vol. 13, No. 4. (g 2006), pp. 337-348.
    by T Bao, T Prowell, V Stearns
    posted to ac chemoprevention serm by worx11 on 2007-10-04 15:55:01 as ** along with 1 group XROWXR
  • Breast cancer management: quality-of-life and cost considerations.
    Pharmacoeconomics, Vol. 21, No. 6. (2003), pp. 383-396.
    posted to ac chemoprevention economic quality_of_life serm by worx11 on 2007-10-04 15:39:05 as **
  • Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
    South Med J, Vol. 99, No. 6. (June 2006), pp. 570-575.
    by TW Downey, SH Foltz, SJ Boccuzzi, MA Omar, KH Kahler
    posted to ac chemoprevention osteoporosis serm by worx11 on 2007-10-04 15:36:59 as **
  • Early discontinuation of tamoxifen: a lesson for oncologists.
    Cancer, Vol. 109, No. 5. (1 March 2007), pp. 832-839.
    by TI Barron, R Connolly, K Bennett, J Feely, MJ Kennedy
    posted to ac chemoprevention serm by worx11 on 2007-10-04 15:36:01 as **
  • Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials.
    Cancer, Vol. 110, No. 7. (20 August 2007), pp. 1621-1628.
    by David R R Buchanan, Ann M M O'mara, Joseph W W Kelaghan, Maria Sgambati, Worta McCaskill-Stevens, Lori Minasian
  • Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    Clin Ther, Vol. 27, No. 8. (August 2005), pp. 1295-1310.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:23:29 as ** along with 1 group XROWXR
  • Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    Support Care Cancer, Vol. 13, No. 12. (December 2005), pp. 975-986.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:21:31 as ** along with 1 group XROWXR
  • The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy.
    Am J Health Syst Pharm, Vol. 64, No. 15 Suppl 10. (1 August 2007)
    by C Downs
    posted to bm medicare medicare_part_d oncology by worx11 on 2007-09-20 20:17:29 as ** along with 1 group XROWXR
  • Formulary issues at a pediatric hospital: experience at Children's National Medical Center.
    Hosp Formul, Vol. 26, No. 6. (June 1991), pp. 500-510.
    by GJ Cohen, SJ Allen
    posted to bm formulary oncology outcomes by worx11 on 2007-09-20 20:14:23 as ** along with 1 group XROWXR
  • Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    J Clin Oncol, Vol. 25, No. 18. (20 June 2007)
    by E Low,
    posted to bm oncology outcomes by worx11 on 2007-09-20 20:11:50 as ** along with 1 group XROWXR
  • European perspective on the costs and cost-effectiveness of cancer therapies.
    J Clin Oncol, Vol. 25, No. 2. (10 January 2007), pp. 191-195.
    by MF Drummond, AR Mason
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:08:00 as ** along with 1 group XROWXR
  • Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Br J Cancer, Vol. 89, No. 4. (18 August 2003), pp. 634-640.
    by A Gordois, P Scuffham, E Warren, S Ward
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:30:11 as ** along with 1 group XROWXR
  • Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Health Technol Assess, Vol. 8, No. 28. (July 2004)
    by K Dalziel, A Round, K Stein, R Garside, A Price
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:43 as ** along with 1 group XROWXR
  • Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Pharmacoeconomics, Vol. 23, No. 5. (2005), pp. 515-526.
    by K Dalziel, A Round, R Garside, K Stein
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:07 as ** along with 1 group XROWXR
  • Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Clin Ther, Vol. 26, No. 11. (November 2004), pp. 1924-1933.
    by E Warren, S Ward, A Gordois, P Scuffham
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:25:17 as ** along with 1 group XROWXR
  • Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Clin Ther, Vol. 26, No. 9. (September 2004), pp. 1546-1561.
  • Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Clin Drug Investig, Vol. 27, No. 2. (2007), pp. 85-93.
  • Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Clin Breast Cancer, Vol. 7, No. 8. (June 2007), pp. 608-618.
    by TE Delea, J Karnon, O Sofrygin, SK Thomas, NL Papo, V Barghout
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:18:02 as ** along with 1 group XROWXR
  • Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Pharmacoeconomics, Vol. 24, No. 3. (2006), pp. 237-250.
    by J Karnon, T Delea, SR Johnston, R Smith, J Brandman, J Sung, PE Goss
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:16:06 as ** along with 1 group XROWXR
  • Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Am J Clin Oncol, Vol. 26, No. 3. (June 2003), pp. 289-296.
    posted to bm cost-utility oncology by worx11 on 2007-09-20 19:15:12 as ** along with 1 group XROWXR
  • Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Breast, Vol. 16, No. 3. (June 2007), pp. 252-261.
    by C Skedgel, D Rayson, R Dewar, T Younis
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:02:57 as ** along with 1 group XROWXR
  • Reimbursement for cancer treatment: coverage of off-label drug indications.
    J Clin Oncol, Vol. 24, No. 19. (1 July 2006), pp. 3206-3208.
    by
    posted to bm oncology by worx11 on 2007-09-20 18:57:10 as ** along with 1 group XROWXR
  • Cost considerations in the management of cancer in the older patient.
    Oncology (Williston Park), Vol. 21, No. 7. (June 2007)
    by JM McKoy, KA Fitzner, BJ Edwards, M Alkhatib, CC Tigue, NJ Nonzee, CR Bolden, CL Bennett
    posted to bm oncology outcomes by worx11 on 2007-09-20 18:54:02 as ** along with 1 group XROWXR
  • Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
    Am J Manag Care, Vol. 13, No. 6 Pt 2. (June 2007), pp. 347-352.
    by DE Mager, ER Cox
    posted to benefit_design bm by worx11 on 2007-09-20 17:46:48 as ** along with 1 group XROWXR
  • Health plans' strategies for managing outpatient specialty pharmaceuticals.
    Health Aff (Millwood), Vol. 25, No. 5. (t 2006), pp. 1332-1339.
    by CD Mullins, DC Lavallee, FG Pradel, AR DeVries, N Caputo
    posted to benefit_design bm by worx11 on 2007-09-20 15:58:39 as ** along with 1 group XROWXR
  • Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors.
    Health Aff (Millwood), Vol. 26, No. 5. (t 2007)
    by P Neuman, MK Strollo, S Guterman, WH Rogers, A Li, AM Rodday, DG Safran
    posted to no-tag by worx11 on 2007-09-20 15:47:59 as ** along with 1 group XROWXR
  • Pharmacy benefit caps and the chronically ill.
    Health Aff (Millwood), Vol. 26, No. 5. (t 2007), pp. 1333-1344.
    posted to benefit_design bm by worx11 on 2007-09-20 15:45:58 as ** along with 1 group XROWXR
  • Bemerkung: Sie können diese Seite wie folgt zitieren: http://www.citeulike.org/user/worx11

    Result page: 1 2 3 4 5 6 7 8 9 10 Next RIS BibTeX RSS
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.